S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Teen workers are in high demand for summer and commanding better pay
AP source: Biden, McCarthy reach 'agreement in principle' to raise debt ceiling as default looms
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Teen workers are in high demand for summer and commanding better pay
AP source: Biden, McCarthy reach 'agreement in principle' to raise debt ceiling as default looms
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Teen workers are in high demand for summer and commanding better pay
AP source: Biden, McCarthy reach 'agreement in principle' to raise debt ceiling as default looms
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Teen workers are in high demand for summer and commanding better pay
AP source: Biden, McCarthy reach 'agreement in principle' to raise debt ceiling as default looms
NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Forecast, Price & News

$0.88
+0.04 (+4.76%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.82
$0.94
50-Day Range
$0.48
$0.88
52-Week Range
$0.47
$2.52
Volume
342,023 shs
Average Volume
162,004 shs
Market Capitalization
$14.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Context Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
354.5% Upside
$4.00 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Context Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.26) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

470th out of 1,018 stocks

Pharmaceutical Preparations Industry

216th out of 498 stocks


CNTX stock logo

About Context Therapeutics (NASDAQ:CNTX) Stock

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Context Therapeutics (CNTX) Gets a Hold from H.C. Wainwright
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Reviewing Context Therapeutics (CNTX) & The Competition
H.C. Wainwright Remains a Hold on Context Therapeutics (CNTX)
H.C. Wainwright downgrades Context Therapeutics (CNTX) to a Hold
See More Headlines
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Company Calendar

Today
5/27/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+354.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.80 per share

Miscellaneous

Free Float
14,903,000
Market Cap
$14.05 million
Optionable
Not Optionable
Beta
2.27

Key Executives

  • Mr. Martin A. LehrMr. Martin A. Lehr (Age 38)
    Co-Founder, Pres, CEO & Director
    Comp: $523.71k
  • Ms. Jennifer Minai-Azary (Age 44)
    CFO & Treasurer
    Comp: $404.33k
  • Mr. Alex C. Levit Esq.Mr. Alex C. Levit Esq. (Age 43)
    Chief Legal Officer & Corp. Sec.
    Comp: $490.82k
  • Dr. Felix Kim Ph.D.
    Co-founder & Chair of Scientific Advisory Board
  • Mr. Christopher Beck M.B.A.
    Sr. VP of Operations
  • Dr. Tarek Sahmoud M.D. (Age 61)
    Ph.D., Chief Medical Officer
  • Dr. Evan G. Dick (Age 70)
    Sr. VP of R&D
  • Ms. Elizabeth Nemchik CPA
    Controller













CNTX Stock - Frequently Asked Questions

Should I buy or sell Context Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNTX, but not buy additional shares or sell existing shares.
View CNTX analyst ratings
or view top-rated stocks.

What is Context Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 1-year price objectives for Context Therapeutics' stock. Their CNTX share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price.
View analysts price targets for CNTX
or view top-rated stocks among Wall Street analysts.

How have CNTX shares performed in 2023?

Context Therapeutics' stock was trading at $0.6517 at the beginning of the year. Since then, CNTX shares have increased by 35.0% and is now trading at $0.88.
View the best growth stocks for 2023 here
.

Are investors shorting Context Therapeutics?

Context Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 100,000 shares, a decrease of 15.6% from the April 30th total of 118,500 shares. Based on an average trading volume of 96,400 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.7% of the company's shares are sold short.
View Context Therapeutics' Short Interest
.

When is Context Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CNTX earnings forecast
.

When did Context Therapeutics IPO?

(CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

What is Context Therapeutics' stock symbol?

Context Therapeutics trades on the NASDAQ under the ticker symbol "CNTX."

Who are Context Therapeutics' major shareholders?

Context Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Two Sigma Investments LP (0.35%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr.
View institutional ownership trends
.

How do I buy shares of Context Therapeutics?

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Context Therapeutics' stock price today?

One share of CNTX stock can currently be purchased for approximately $0.88.

How much money does Context Therapeutics make?

Context Therapeutics (NASDAQ:CNTX) has a market capitalization of $14.05 million. The company earns $-14,840,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How can I contact Context Therapeutics?

Context Therapeutics' mailing address is 3675 Market Street, Philadelphia, Pennsylvania 19104. The official website for the company is www.contexttherapeutics.com. The company can be reached via phone at 267-225-7416.

This page (NASDAQ:CNTX) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -